Cooperative Treatment of Gastric Cancer Using B7-H7 SiRNA and Docetaxel; How Could They Modify Their Effectiveness?

Overview

Journal Adv Pharm Bull

Date 2023 Aug 30

PMID 37646055

Authors

Nadia Bolandi

Mohammad Hassan Khadem Ansari

Yousef Rasmi

Behzad Baradaran

Affiliations

Soon will be listed here.

Abstract

Purpose: Despite the high prevalence of gastric cancer (GC), drug resistance is a major problem for effective chemotherapy. B7-H7 is a novel member of the B7 superfamily and is expressed in most common cancers. However, the role of B7-H7 on the aggressiveness of GC and chemosensitivity has remained unknown. Therefore, this study was designed to assess the effect of B7-H7 suppression using small interference RNA (siRNA) in combination with docetaxel on GC cells.

Methods: MTT test was applied to determine the IC50 of docetaxel and the combined effect of B7-H7 siRNA and docetaxel on the viability of the MKN-45 cells. To determine B7-H7, BCL-2, BAX, and caspase-3-8-9 genes expression, qRT-PCR was performed. Furthermore, flow cytometry was applied to evaluate apoptosis and the cell cycle status. Finally, to evaluate the effect of this combination therapy on migratory capacity and colony-forming ability, wound healing assay and colony formation test were employed, respectively.

Results: B7-H7 suppression increased the chemo-sensitivity of MKN-45 cells to docetaxel. The expression of B7-H7 mRNA was reduced after using B7-H7 siRNA and docetaxel in MKN-45 GC cells. Also, B7-H7 suppression alongside docetaxel reduced cell migration and colony formation rate, arrested the cell cycle at the G2-M phase, and induced apoptosis by modulating the expression of apoptotic target genes.

Conclusion: B7-H7 plays a significant role in the chemo-sensitivity and pathogenesis of GC. Therefore, B7-H7 suppression, in combination with docetaxel, may be a promising therapeutic approach in treating GC.

References

Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B . The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 2017; 7(3):339-348. PMC: 5651054. DOI: 10.15171/apb.2017.041. View

Zhu Y, Yao S, Iliopoulou B, Han X, Augustine M, Xu H . B7-H5 costimulates human T cells via CD28H. Nat Commun. 2013; 4:2043. PMC: 3698612. DOI: 10.1038/ncomms3043. View

Mansoori B, Sandoghchian Shotorbani S, Baradaran B . RNA interference and its role in cancer therapy. Adv Pharm Bull. 2014; 4(4):313-21. PMC: 4137419. DOI: 10.5681/apb.2014.046. View

Marin J, Al-Abdulla R, Lozano E, Briz O, Bujanda L, Banales J . Mechanisms of Resistance to Chemotherapy in Gastric Cancer. Anticancer Agents Med Chem. 2015; 16(3):318-34. DOI: 10.2174/1871520615666150803125121. View

Dong L, Xie L, Li M, Dai H, Wang X, Wang P . Downregulation of B7-H4 suppresses tumor progression of hepatocellular carcinoma. Sci Rep. 2019; 9(1):14854. PMC: 6795893. DOI: 10.1038/s41598-019-51253-2. View

Janakiram M, Chinai J, Fineberg S, Fiser A, Montagna C, Medavarapu R . Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein. Clin Cancer Res. 2015; 21(10):2359-66. PMC: 4433806. DOI: 10.1158/1078-0432.CCR-14-1495. View

Casamayor M, Morlock R, Maeda H, Ajani J . Targeted literature review of the global burden of gastric cancer. Ecancermedicalscience. 2019; 12:883. PMC: 6345079. DOI: 10.3332/ecancer.2018.883. View

Chen L, Zhu D, Feng J, Zhou Y, Wang Q, Feng H . Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients. Cancer Cell Int. 2019; 19:101. PMC: 6469208. DOI: 10.1186/s12935-019-0813-2. View

Cheng H, Janakiram M, Borczuk A, Lin J, Qiu W, Liu H . HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status. Clin Cancer Res. 2016; 23(3):825-832. PMC: 5290088. DOI: 10.1158/1078-0432.CCR-15-3071. View

10.

Musacchio A, Salmon E . The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol. 2007; 8(5):379-93. DOI: 10.1038/nrm2163. View

11.

Chen D, Chen W, Xu Y, Zhu M, Xiao Y, Shen Y . Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target. J Med Genet. 2018; 56(1):43-49. DOI: 10.1136/jmedgenet-2018-105454. View

12.

Zhang B, Sun J, Yao X, Li J, Tu Y, Yao F . Knockdown of B7H6 inhibits tumor progression in triple-negative breast cancer. Oncol Lett. 2018; 16(1):91-96. PMC: 6019890. DOI: 10.3892/ol.2018.8689. View

13.

Wu F, Wang J, Ke X . Knockdown of B7-H6 inhibits tumor progression and enhances chemosensitivity in B-cell non-Hodgkin lymphoma. Int J Oncol. 2016; 48(4):1561-70. DOI: 10.3892/ijo.2016.3393. View

14.

Zhu Z, Dong W . Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma. Onco Targets Ther. 2018; 11:1563-1570. PMC: 5865557. DOI: 10.2147/OTT.S160493. View

15.

Zhao R, Chinai J, Buhl S, Scandiuzzi L, Ray A, Jeon H . HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc Natl Acad Sci U S A. 2013; 110(24):9879-84. PMC: 3683785. DOI: 10.1073/pnas.1303524110. View

16.

Asadzadeh Z, Mansoori B, Mohammadi A, Kazemi T, Mokhtarzadeh A, Shanehbandi D . The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy. Biomed Pharmacother. 2021; 137:111364. DOI: 10.1016/j.biopha.2021.111364. View

17.

Ni L, Dong C . New B7 Family Checkpoints in Human Cancers. Mol Cancer Ther. 2017; 16(7):1203-1211. PMC: 5568666. DOI: 10.1158/1535-7163.MCT-16-0761. View

18.

Leung J, Suh W . The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. Immune Netw. 2015; 14(6):265-76. PMC: 4275384. DOI: 10.4110/in.2014.14.6.265. View

19.

Lin G, Ye H, Wang J, Chen S, Chen X, Zhang C . Immune Checkpoint Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 is Upregulated and Independently Predicts Unfavorable Prognosis in Bladder Urothelial Carcinoma. Nephron. 2019; 141(4):256-264. DOI: 10.1159/000495887. View

20.

Suzuki T, Yoshida K, Wada Y, Hamai Y, Sentani K, Oue N . Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer. Oncol Rep. 2007; 18(2):329-36. View